NORTHERN URANIUM CORP ORD by Northern Uranium Corp Stock (OTC: NRUNF)

Latest news for NORTHERN URANIUM CORP ORD by Northern Uranium Corp (OTC:NRUNF) Stock

NORTHERN URANIUM CORP ORD by Northern Uranium Corp

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">HubSpot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>)</h3>
<ul>
<li>According to a Bloomberg report citing people with knowledge of the matter on July 10, Google parent Alphabet ditched its efforts to acquire HubSpot after the two companies failed to reach detailed discussions on a potential deal. The company's stock fell around 16% over the past month and has a <a href="https://www.benzinga.com/quote/HUBS">52-week low of $407.23</a>.</li>
<li>RSI Value: 29.55</li>
<li>HUBS Price Action: Shares of HubSpot fell 0.3% to close at $479.82 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest HUBS news.</li>
</ul>
<h3 class="wp-block-heading">Nutanix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On June 21, Morgan Stanley analyst Meta Marshall maintained Nutanix with an Equal-Weight rating and lowered the price target from $72 to $62. The company's stock fell around 11% over the past five days. It <a href="https://www.benzinga.com/quote/NTNX">has a 52-week low</a> of $28.49.</li>
<li>RSI Value: 29.47</li>
<li>NTNX Price Action: Shares of Nutanix rose 0.8% to close at $48.30 on Friday.</li>
<li>Benzinga Pro's charting tool helped identify the trend in Nutanix stock.</li>
</ul>
<h3 class="wp-block-heading">Crowdstrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</h3>
<ul>
<li>On July 19, a widespread CrowdStrike issue resulted in Windows computers crashing worldwide, affecting everyone from airports and airlines to media services, banks, and many other businesses.. The company's stock dipped around 18% over the past five days and has a 52-week lo<a href="https://www.benzinga.com/quote/CRWD">w of $140.52.</a></li>
<li>RSI Value: 24.03</li>
<li>CRWD Price Action: Shares of Crowdstrike fell 11.1% to close at $304.96 on Friday.</li>
<li>Benzinga Pro's signals feature notified of a potential breakout in Crowdstrike shares.</li>
</ul>
<h3 class="wp-block-heading">Corsair Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>)</h3>
<ul>
<li>On July 18, Corsair Gaming reported preliminary results for the second quarter. Corsair announced that it expects to report second-quarter revenue of approximately $261 million versus estimates of $319.977 million, according to Benzinga Pro. The company's shares lost around 17% over the past five days. The company's 52-week low is $8.12.</li>
<li>RSI Value: 24.87</li>
<li>CRSR Price Action: Shares of Corsair Gaming fell 11.8% to close at $8.57 on Friday.</li>
<li>Benzinga Pro's earnings calendar was used to track CRSR upcoming earnings report.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39864861/alphabet-dell-and-2-other-stocks-insiders-are-selling">Alphabet, Dell And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

CRSR

CRWD

HUBS

NTNX

Top 4 Tech Stocks That May Explode In July

Stifel analyst Chris O'Cull maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Hold and lowers the price target from $285 to $265.

Price Target

Analyst Ratings

Stifel Maintains Hold on McDonald's, Lowers Price Target to $265

Stifel analyst Mark Kelley maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Hold and lowers the price target from $67 to $65.

ETSY

Stifel Maintains Hold on Etsy, Lowers Price Target to $65

Rosenblatt analyst Hans Mosesmann maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy and raises the price target from $210 to $250.

Rosenblatt Maintains Buy on Texas Instruments, Raises Price Target to $250

Selective Insurance Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) posted weak quarterly results, after the <a href="https://widgets.benzinga.com/quote/SIGI/news">closing bell on Thursday</a>.
Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
&#8220;This was a challenging quarter. We did not meet our high standard as underwriting performance fell below our target. The unfavorable prior year casualty reserve development was driven by elevated loss emergence in the quarter reflecting higher severity that we attribute to social inflation. Our reserving action is predicated on our in-depth quarterly reserve review and further strengthening to address elevated and uncertain loss trends,&#8221; said John J. Marchioni, Chairman, President and Chief Executive Officer.
Marchioni added, &#8220;We have a very stable underwriting portfolio. To address our updated view of loss costs, we are responding with additional price increases. Our renewal pure price increase across all insurance segments was 9.1% in the quarter, including 7.9% for Standard Commercial Lines. General liability renewal pure pricing increased to 7.6%, up over a point from the first quarter. We expect Standard Commercial Lines renewal pure price will trend higher in the second half of 2024.&#8221;
Selective shares fell 18.2% to close at $82.08 on Friday.
These analysts made changes to their price targets on Selective following the announcement.
<ul>
<li>Piper Sandler analyst Paul Newsome maintained Selective Insurance with a Neutral rating and lowered the price target from $104 to $85.</li>
<li>Keefe, Bruyette &amp; Woods analyst Meyer Shields upgraded Selective Insurance from Market Perform to Outperform, but cut the price target from $104 to $99.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39876573/verizon-sap-and-3-stocks-to-watch-heading-into-monday">Verizon, SAP And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>

Earnings

SIGI

Selective Insurance Analysts Cut Their Forecasts After Downbeat Earnings

The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors
TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company's venture with Dr. Alon Silberman that focuses on drug discovery and development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, has validated the potential&nbsp;significant involvement of its target SLC25 carrier protein, using Non-Small Cell Lung Cancer ("NSCLC") cells with diverse genetic backgrounds. MitoCareX demonstrated the discovery by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors.
NSCLC is the most typical form of lung cancer and, according to <a href="https://www.globenewswire.com/Tracker?data=3IHwPKxZpUwyKn2YPv_thRMP_kFLxBKvuumiyTmY1ElomYDkQrHxQQKh8Q2rpcjK9LYg3iDj5BReicx9OGDots4LCSsGcGxG_iIsWrUpeubJamQfjh0vT0U_QsckI-HTHRFAQPITGaJtpUkQgUGka1n8SA4my1Evn47t74D5kIe9e2jyD1bXHRQ_ENZ3K0ny">ResearchAndMarkets.com</a>, the NSCLC Market is projected to reach a value of $59.77 billion by the year 2030. Accounting for 80%-85% of all lung cancer cases globally, NSCLC has driven key market players to focus on continuous innovation and efficacy enhancement in therapeutics. This prominence is due to lung cancer's status as one of the most common cancers worldwide, contributing to a significant number of global deaths.

Biotech

General

SPRC

SciSparc Announces MitoCareX Confirms Potential Significant Role Of Its Drug Target In NSCLC

WIIM

HEPA

Hepion Pharmaceuticals shares are trading higher after the company announced it entered into a definitive merger agreement with Pharma Two B. The company announced a $2.9 million private placement of non-convertible senior notes to institutional investors.

Melius Research analyst Conor Cunningham initiates coverage on Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Hold rating and announces Price Target of $15.

Initiation

LYFT

Melius Research Initiates Coverage On Lyft with Hold Rating, Announces Price Target of $15

EF Hutton analyst Jason Kolbert initiates coverage on Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy rating and announces Price Target of $46.

AVXL

EF Hutton Initiates Coverage On Anavex Life Sciences with Buy Rating, Announces Price Target of $46

RR: 100% &#x7C; <a href="https://www.benzinga.com//node/39878249">Richtech Robotics Celebrates Completion of Installation of ADAM at Ghost Kitchens inside Dawsonville, GA Walmart</a>
&nbsp;
MIRA: 84% &#x7C; <a href="https://www.benzinga.com//node/39881033">MIRA Pharmaceuticals Announces New Preclinical Study Results Highlighting Potential Advantages Of Novel Oral Ketamine Analog Ketamir-2 For Neurological And Neuropsychiatric Disorders</a>
&nbsp;
HEPA: 62% &#x7C; <a href="https://www.benzinga.com//node/39881066">Pharma Two B To Go Public Through Merger With Hepion Pharmaceuticals; Co. Also Announces $2.9M Private Placement Of Non-Convertible Senior Notes To Institutional Investors</a>

Movers

MIRA

Market-Moving News for July 22nd

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $26 price target.

Reiteration

PHAT

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Melius Research analyst Conor Cunningham initiates coverage on Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Hold rating and announces Price Target of $77.

UBER

Melius Research Initiates Coverage On Uber Technologies with Hold Rating, Announces Price Target of $77

ON Semiconductor Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares are trading higher after the company signed a multi-year agreement with Volkswagen Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLKAF#OTC">VLKAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) to provide solutions for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39878255/onsemi-selected-to-power-volkswagen-groups-next-generation-electric-vehicles" rel="noreferrer noopener">vehicle lineup across multiple brands</a>.
As per the deal, ON Semiconductor will supply a comprehensive power box solution for Volkswagen&#8217;s next-generation traction inverter within its Scalable Systems Platform (SSP).
onsemi&#8217;s EliteSiC M3e MOSFET-based power box offers higher power and efficiency in a compact design, enhancing heat management and extending EV range. Volkswagen Group can seamlessly adopt future EliteSiC platforms, staying at the forefront of EV innovation.
Volkswagen Group will benefit from onsemi&#8217;s investment in a new silicon carbide plant in the Czech Republic, which will streamline the supply chain and logistics for traction inverter systems, enhancing manufacturing efficiency.
Till von Bothmer, Senior Vice President VW Group Procurement for Powertrain, said, &#8220;On top of the verticalization, onsemi has furthermore provided a resilient supply concept with regional silicon carbide fabs across Asia, Europe and the U.S. In addition, onsemi will continuously provide the latest SiC generation to ensure competitiveness.&#8221;
Earlier this month, ON Semiconductor announced it had completed the <a target="_blank" href="https://www.benzinga.com/news/24/07/39608561/what-happened-with-on-semiconductor-stock-today" rel="noreferrer noopener">acquisition of SWIR Vision Systems</a>.
In June, On Semiconductor announced a&nbsp;restructuring plan&nbsp;that included reducing its workforce by 1,000 employees and consolidating nine sites to optimize its manufacturing network <a target="_blank" href="https://www.benzinga.com/news/24/06/39339784/why-are-on-semiconductor-shares-trading-lower-friday" rel="noreferrer noopener">and consolidate its global corporate footprint</a>.
Investors can gain exposure to ON stock via First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCLN#NASDAQ">QCLN</a>) and Return Stacked Bonds &amp; Managed Futures ETF Veridien Climate Action ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLIA#NYSE">CLIA</a>).
<h2 class="wp-block-heading">ON Stock Prediction 2024</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of ON Semiconductor have an average 1-year price target of $86.53, representing an expected upside of 19.3%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 1 analysts have bearish recommendations on ON Semiconductor, while 14 analysts have bullish ratings. The street high price target from B. Riley Securities is $103.0, while the street low from Morgan Stanley is $65.0.
Price Action: ON shares are up 3.06% at $74.75 premarket at the last check Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Large Cap

Contracts

CLIA

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

VLKAF

VWAGY

ON Semiconductor Seals Multi-Year Deal with Volkswagen for Advanced EV Solutions; Stock Gains

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>. 
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">Atlantica Sustainable Infrastructure plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AY#NASDAQ">AY</a>)</h3>
<ul>
<li>Dividend Yield: 8.07%</li>
<li>Seaport Global analyst Angie Storozynski downgraded the stock from Buy to Neutral on May 29. This analyst has an accuracy rate of 74%.</li>
<li>BMO Capital analyst James Thalacker maintained a Market Perform rating and raised the price target from $20 to $23 on May 10. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On May 28, the company announced it entered into a definitive agreement to be acquired by Energy Capital Partners.</li>
<li>Benzinga Pro's real-time newsfeed <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">alerted to latest AY news</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="687" height="733" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042207/Screenshot-2024-07-22-at-1.52.00-PM.png" alt="" class="wp-image-448064" style="width:428px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042207/Screenshot-2024-07-22-at-1.52.00-PM.png 687w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042207/Screenshot-2024-07-22-at-1.52.00-PM-281x300.png 281w" sizes="(max-width: 687px) 100vw, 687px" /></a></figure>
<h3 class="wp-block-heading">UGI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>)</h3>
<ul>
<li>Dividend Yield: 6.16%</li>
<li>Wells Fargo analyst Sarah Akers maintained an Equal-Weight rating and cut the price target from $28 to $27 on May 3. This analyst has an accuracy rate of 66%.</li>
<li>Mizuho analyst Gabriel Moreen maintained a Neutral rating and raised the price target from $26 to $27 on April 17. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: UGI is scheduled to announce the results of its third fiscal quarter earnings after the closing bell on Aug. 7.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">Benzinga Pro's charting tool</a> helped identify the trend in UGI's stock.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="688" height="752" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042243/Screenshot-2024-07-22-at-1.52.37-PM.png" alt="" class="wp-image-448065" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042243/Screenshot-2024-07-22-at-1.52.37-PM.png 688w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042243/Screenshot-2024-07-22-at-1.52.37-PM-274x300.png 274w" sizes="(max-width: 688px) 100vw, 688px" /></a></figure>
<h3 class="wp-block-heading">Avista Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>)</h3>
<ul>
<li>Dividend Yield: 5.17%</li>
<li>Mizuho analyst Anthony Crowdell upgraded the stock from Underperform to Neutral and raised the price target from $32 to $36 on May 3. This analyst has an accuracy rate of 63%.</li>
<li>Guggenheim analyst Shahriar Pourreza upgraded the stock from Sell to Neutral with a price target of $34 on Jan. 22. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: Avista is expected to hold its quarterly conference call and webcast to discuss second quarter results on Wednesday, Aug. 7.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">breakout in AVA's shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="657" height="757" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042329/Screenshot-2024-07-22-at-1.53.24-PM.png" alt="" class="wp-image-448066" style="width:397px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042329/Screenshot-2024-07-22-at-1.53.24-PM.png 657w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042329/Screenshot-2024-07-22-at-1.53.24-PM-260x300.png 260w" sizes="(max-width: 657px) 100vw, 657px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39876573/verizon-sap-and-3-stocks-to-watch-heading-into-monday">Verizon, SAP And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Dividends

Wall Street's Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields

<a href="https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/ex_701112.htm">https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/ex_701112.htm</a>
&nbsp;

Management

SAVA

Cassava Sciences Executive Chairman Rick Barry Issues An Open Letter To "Shareholders, Employees, Principal Investigators, Patients And Their Loved Ones" On July 21, 2024

Keefe, Bruyette &amp; Woods analyst Meyer Shields upgrades Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) from Market Perform to Outperform and lowers the price target from $104 to $99.

Upgrades

Keefe, Bruyette & Woods Upgrades Selective Insurance Gr to Outperform, Lowers Price Target to $99

MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.

Accenture To Acquire Camelot Management Consultants To Enhance SAP And AI-Driven Supply Chain Capabilities

Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

NORTHERN URANIUM CORP ORD by Northern Uranium Corp

News

Latest news for NORTHERN URANIUM CORP ORD by Northern Uranium Corp (OTC:NRUNF) Stock